There is increasing evidence for the role of serum APE1/Ref-1 as a new diagnostic biomarker for hepatocellular carcinoma [69], renal cell carcinoma and hepatobiliary carcinoma [70], cholangiocarcinoma [71], non-small cell lung cancer [72], and gastric cancer [73] as shown in Table 2. This evidence concerns the gene APEX1 and cholangiocarcinoma.